chugai

Chugai Pharma Taiwan (CPT) led its team to Taitung Zhiben on February 24, 2026, to collaborate with P.K. EverCovenant in hosting the "Low-Carbon Rice Adoption Unveiling Ceremony." This initiative not only symbolizes the company's firm commitment to Environmental protection (E), Social responsibility (S), and Governance (G), and the implementation of Chugai Group's TOP I 2030 environmental sustainability goals, but also demonstrates how the pharmaceutical industry's definition of "health" has extended from the human body to encompass the sustainable development of land and ecosystems.

This adoption program partners with "P.K. EverCovenant Biotech Co., Ltd." utilizing its core technology—the SPRI Low-Carbon Farming Method (System of Probiotic and Rice Intensification)—to revitalize land that has been fallow for decades. This represents a revolution in rice cultivation technology, with key highlights including:

• Maximum Carbon Reduction: By utilizing biotechnology to enhance plant immunity and employing probiotic farming methods, this approach can effectively reduce carbon emissions by 62% compared to traditional farming practices.
• Energy and Water Conservation: By implementing irrigation system patents of P.K. Covenant that enabling water consumption by 30% and increasing probiotic growth potential.
• Zero Chemical Pollution: The entire process uses no pesticides, chemical fertilizers, or herbicides. Probiotics activate soil microbiomes and enhance crop immunity.
• Ecological Harmony: Low-carbon rice fields employ appropriate plant density, combined with no pesticides or chemical fertilizers, prevents soil burden while restoring biodiversity in the fields, realizing the concept of "making a covenant with the land." In these pesticide-free low-carbon rice fields, one can easily spot Indian Red Admirals, endemic subspecies of Ring-necked Pheasants, Grey Herons, and other wildlife.

CPT states that the core mission of the pharmaceutical industry is to protect life and health, and healthy life cannot be separated from pure land and water sources. The decision to adopt and contract-farm low-carbon rice stems from the high compatibility between P.K. EverCovenant's sustainable farming methods and Chugai Pharma's core values of "people-oriented, sustainable development." It is worth noting that P.K. EverCovenant Biotech Co., Ltd, has developed "ShenMei Rice" specifically designed for patients with kidney disease. This low-protein rice contains 38.7% less protein than regular white rice, effectively reducing the burden on the kidneys. With ShenMei Rice, kidney disease patients can still enjoy tasty rice while strictly controlling their protein intake and maintaining adequate calorie consumption, thereby improving their quality of life.

At the unveiling ceremony, the team from CPT also personally planted seedlings of low-carbon rice."What we're adopting is not just a rice field, but a concrete investment in a low-carbon future," shared the Chugai Pharma leadership team at the unveiling ceremony. "Through supporting innovative and sustainable farming technologies, we hope to contribute to Taiwan's low-carbon agriculture, starting from the source of our dining tables."

The on-site unveiling ceremony symbolizes CPT's deep connection with land and ecosystems. In the future, the low-carbon rice produced will serve as a carrier of the company's sustainability spirit, conveying this care for the land to every partner.

Through this adoption initiative, CPT once again demonstrates that corporate influence extends beyond offices and laboratories to take root in natural fields. Partnering with P.K. EverCovenant, CPT plants seeds of sustainability and harvest hope for a low-carbon and healthy future.